AZD 6244

mitogen-activated protein kinase kinase 1 ; Homo sapiens







150 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34515877 Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. 2022 Feb 1
2 35170228 Effect of food on capsule and granule formulations of selumetinib. 2022 Apr 1
3 35171389 Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. 2022 Feb 16 4
4 35210278 ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. 2022 Mar 1
5 35246426 Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. 2022 Mar 4 2
6 35250023 Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. 2022 Mar 7 2
7 35406545 Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas. 2022 Mar 31 1
8 35410754 A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib. 2022 Apr 2
9 33273059 AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. 2021 Feb 3
10 33405090 Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. 2021 Jun 2
11 33536190 Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. 2021 Apr 1
12 33631016 A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. 2021 Oct 1 1
13 33683166 Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. 2021 May 1
14 33808483 Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico. 2021 Mar 30 1
15 33903938 Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. 2021 Aug 2
16 33978635 Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. 2021 Jan-Dec 1
17 34196005 Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. 2021 Nov 2
18 34680330 Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. 2021 Oct 15 1
19 34831012 MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells. 2021 Nov 22 1
20 32108293 Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. 2020 Apr 3
21 32504375 Selumetinib: First Approval. 2020 Jun 3
22 32629964 The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. 2020 Jun 30 2
23 32880495 Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. 2020 Nov 1
24 33099927 Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells. 2020 Jul-Aug 1
25 30317534 Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. 2019 Jun 3
26 30972766 MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. 2019 Sep 1
27 31151904 Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. 2019 Jul 1
28 31200828 Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. 2019 Jul 1
29 31409052 Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. 2019 Aug 12 1
30 28833380 Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. 2018 Jan 1
31 28986121 A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses. 2018 Jan 1
32 29216787 MEK inhibitors under development for treatment of non-small-cell lung cancer. 2018 Jan 1
33 29526823 Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. 2018 Jun 1
34 29528792 Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). 2018 Apr 20 3
35 29737325 The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. 2018 May 8 2
36 29915160 The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. 2018 Aug 15 1
37 30414267 Effects of Erythromycin on the Proliferation and Apoptosis of Cultured Nasal Polyp-Derived Cells and the Extracellular Signal-Regulated Kinase (ERK)/Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway. 2018 Nov 10 1
38 27889832 Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. 2017 Feb 1
39 28019010 Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects. 2017 May 1
40 28212559 The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo. 2017 Mar 28 2
41 28264648 A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. 2017 Mar 6 3
42 28283692 Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. 2017 Jun 2
43 28326681 Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. 2017 May 2
44 28385507 Discovery of a cobalt complex with high MEK1 binding affinity. 2017 May 15 1
45 28424891 A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. 2017 Oct 3
46 28791489 Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway. 2017 Nov 1
47 28819429 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. 2017 3
48 28849200 Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. 2017 Oct 3
49 28931905 Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. 2017 Sep 20 2
50 26446942 A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. 2016 Mar 1 3